相关实验视频
Updated: Feb 28, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.4K
常规临床实践中超重/肥胖患者心血管事件的二次预防
medRxiv : the preprint server for health sciences
|February 27, 2026
概括
类似葡萄糖-1受体激动剂 (GLP-1RA) 在超重患者中显示出降低心血管事件的潜力. 与芬特明-托皮拉相比,GLP-1 RAs显示主要心血管或脑血管不良事件的风险较低.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RA) 在没有糖尿病的超重/肥胖患者中对心血管疾病的二次预防有效.
- 与其他抗肥胖药物相比,GLP-1 RAs的比较有效性尚未得到充分证实.
研究的目的:
- 为了比较GLP-1RA与其他抗肥胖药物预防心血管事件的有效性.
主要方法:
- 使用电子健康记录 (Truveta数据库) 的回顾性观察队列研究.
- 包括BMI≥27kg/m2的成年人,有心血管疾病史,没有糖尿病.
- 主要终点:主要心血管或脑血管不良事件 (MACCE) 的时间.
主要成果:
- 在未加权分析中,GLP-1 RA的使用与MACCE危险降低有关,而不是布洛普-纳尔特雷和芬特明-托皮拉.
- 在权重分析中,GLP-1 RA与较低的MACCE危险性无关,而不是布洛普-纳尔德.
- GLP-1 RA与MACCE危险性相比,与芬特明托皮拉相比较低 (aHR为0.61;95% CI为0.41-0.91).
结论:
- 对GLP-1RA的处方与相比,与芬特明托皮拉相比,与随后的MACCE风险降低有关.
- 在这种患者群体中,GLP-1 RAs可能会比芬特明托皮拉马特提供心血管益处.
相关概念视频
Atherosclerosis III: Management
516
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
516
Coronary Artery Disease IV: Preventive Measures
773
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
773
Drug Dosing: Obese Patients
315
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
315
Acute Coronary Syndrome IV: Interprofessional Care
347
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
347
Coronary Artery Disease V: Interprofessional Care
343
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
343
Hypertension IV: Drug Therapy and Lifestyle Modifications
790
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
790

